New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

(2012) Roger H. Unger et al.   JOURNAL OF CLINICAL INVESTIGATION

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes

(2011) P. C. M. van Poppel et al.   DIABETES CARE

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

(2011) R. Kodera et al.   DIABETOLOGIA

Glucagon-like peptide–1 suppresses advanced glycation end product–induced monocyte chemoattractant protein–1 expression in mesangial cells by reducing advanced glycation end product receptor level

(2011) Yuji Ishibashi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

(2008) R CHRISTOPHER et al.   CLINICAL THERAPEUTICS

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

(2008) H. He et al.   DRUG METABOLISM AND DISPOSITION